Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Revenue: 2021-2025

Historic Revenue for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Sep 2025 value amounting to $180.9 million.

  • Kiniksa Pharmaceuticals International's Revenue rose 61.17% to $180.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $598.0 million, marking a year-over-year increase of 55.68%. This contributed to the annual value of $423.2 million for FY2024, which is 56.60% up from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported Revenue of $180.9 million as of Q3 2025, which was up 15.34% from $156.8 million recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Revenue peaked at $180.9 million during Q3 2025, and registered a low of -$148.3 million during Q4 2022.
  • Over the past 3 years, Kiniksa Pharmaceuticals International's median Revenue value was $108.6 million (recorded in 2024), while the average stood at $106.3 million.
  • The largest annual percentage gain for Kiniksa Pharmaceuticals International's Revenue in the last 5 years was 719.64% (2022), contrasted with its biggest fall of 891.12% (2022).
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Revenue (Quarterly) stood at $18.7 million in 2021, then slumped by 891.12% to -$148.3 million in 2022, then skyrocketed by 156.24% to $83.4 million in 2023, then soared by 46.93% to $122.5 million in 2024, then skyrocketed by 61.17% to $180.9 million in 2025.
  • Its Revenue was $180.9 million in Q3 2025, compared to $156.8 million in Q2 2025 and $137.8 million in Q1 2025.